What's Next for Esperion Therapeutics' Cholesterol-Lowering Drug

Esperion Therapeutics (NASDAQ: ESPR) reported positive results from the last four pivotal phase 3 trials of its cholesterol-lowering drug, bempedoic acid, on Oct. 29. The successful study clears the way for management to file for FDA approval of bempedoic acid next year, putting it on pace to battle for a share in a multibillion-dollar treatment market. Here's what the company's telling investors about its future.